Drug Profile
ME 344
Alternative Names: ME-344; NV-344Latest Information Update: 07 Jul 2023
Price :
$50
*
At a glance
- Originator Novogen
- Developer MEI Pharma; Sarah Cannon Research Institute; Spanish National Cancer Research Centre; Tennessee Oncology
- Class Antineoplastics; Isoflavones; Small molecules
- Mechanism of Action Mitochondrial oxidative phosphorylation inhibitors; MTORC1 protein inhibitors; MTORC2 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Colorectal cancer
- Preclinical Acute myeloid leukaemia
- No development reported HER2 negative breast cancer
- Discontinued Cervical cancer; Ovarian cancer; Small cell lung cancer
Most Recent Events
- 08 May 2023 Phase-I clinical trials in Colorectal cancer (Combination therapy, Second-line therapy or greater, Metastatic disease) in USA (IV) (NCT05824559)
- 30 Apr 2023 MEI Pharma plans a phase Ib trial for Colorectal cancer (Combination therapy, Second-line therapy or greater, Metastatic disease) (IV) in April 2023 (NCT05824559)
- 01 Dec 2022 US FDA approves IND application for ME 344 plus Avastin®(bevacizumab) in Colorectal cancer